Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs
April 03, 2023 08:00 ET
|
Vaccinex, Inc.
Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer’s study in April 2023 with topline data anticipated mid-2024 Completed enrollment of 36 patients required for...
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
March 23, 2023 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, “Vaccinex”), a clinical-stage biotechnology company pioneering a differentiated approach to treating...
Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
March 21, 2023 08:30 ET
|
Vaccinex, Inc.
The study is intended to assess whether pepinemab can reverse the suppressive tumor microenvironment found in PDAC, thereby facilitating the anti-tumor activity of immune checkpoint blockade ...
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis
March 09, 2023 08:00 ET
|
Vaccinex, Inc.
Interim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks after initiating treatment The open-label Phase 1b/2 KEYNOTE B-84 study...
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
January 09, 2023 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex Announces $3.8 Million Private Placement
November 28, 2022 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update
November 14, 2022 08:30 ET
|
Vaccinex, Inc.
Promising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patient enrollment continues in the...
Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer
November 10, 2022 09:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs
August 15, 2022 08:10 ET
|
Vaccinex, Inc.
Promising initial responses in continuing Phase 1b/2 KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Phase 2 SIGNAL-HD Study Published in...
Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation
August 08, 2022 11:00 ET
|
Vaccinex, Inc.
Data suggest that pepinemab slows or prevents cognitive decline in Huntington’s Disease (HD) Results highlight the potential for impact on other neurodegenerative and neuroinflammatory diseases...